33 Results for "

hyperparathyroidism

" in MedChemExpress (MCE) Product Catalog:
Products (33)

33 Results for "hyperparathyroidism" in MCE Product Catalog:

16
16 Publications Verification
Cat. No.: HY-50919
CAS No.: 131918-61-1
Target:  

VD/VDR

Research Areas:  

Metabolic Disease Cancer

Paricalcitol, a vitamin D analogue, is a vitamin D receptor agonist, used for the prevention and treatment of secondary hyperparathyroidism (excessive secretion of parathyroid hormone) associated with chronic renal failure.
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-32339
CAS No.: 103909-75-7
Synonyms: 22-Oxacalcitriol
Maxacalcitol (22-Oxacalcitriol), a vitamin D3 (HY-15398) analog, is an orally active VDR agonist. Maxacalcitol has a limited calcemic effect. Maxacalcitol has the potential for psoriasis and hyperparathyroidism research .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-17613
CAS No.: 870964-67-3
Synonyms: KHK7580
Target:  

CaSR

Research Areas:  

Metabolic Disease

Evocalcet (KHK7580) is an orally active calcium sensing receptor (CaSR) agonist. Evocalcet inhibits the secretion of parathyroid hormone (PTH) from parathyroid gland cells. Evocalcet can be used for the research of hyperparathyroidism .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P1955A
CAS No.: 1334237-71-6
Synonyms: Velcalcetide hydrochloride; AMG 416 hydrochloride; KAI-4169 hydrochloride
Target:  

CaSR

Research Areas:  

Endocrinology

Etelcalcetide hydrochloride (AMG 416 hydrochloride; KAI-4169 hydrochloride) is a synthetic calcimimetic as an activator of the calcium sensing receptor (CaSR). Etelcalcetide hydrochloride is effective in lowering parathyroid hormone (PTH) concentrations in patients receiving dialysis with secondary hyperparathyroidism receiving hemodialysis, which is promising for research in the field of secondary hyperparathyroidism and chronic kidney disease .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-13995A
CAS No.: 152751-57-0
Purity:  ≥98.0%
Target:  

FXR

Research Areas:  

Metabolic Disease Endocrinology

Sevelamer hydrochloride is an orally active polymeric phosphate binder and bile acid sequestrant. Sevelamer hydrochloride binds dietary phosphate in the gastrointestinal tract, reducing phosphate absorption and serum phosphorus levels, and reduces urinary phosphate excretion. Sevelamer hydrochloride binds polyanion bile acids, increases bile acid faecal excretion, and reduces total cholesterol and LDL cholesterol levels. Sevelamer hydrochloride can be used for the research of hyperphosphataemia, hyperparathyroidism, chronic renal failure, kidney disease, and type 2 diabetes .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-13995B
CAS No.: 845273-93-0
Target:  

FXR

Research Areas:  

Metabolic Disease Endocrinology

Sevelamer carbonate is an orally active polymeric phosphate binder and bile acid sequestrant. Sevelamer carbonate binds dietary phosphate in the gastrointestinal tract, reducing phosphate absorption and serum phosphorus levels, and reduces urinary phosphate excretion. Sevelamer carbonate binds polyanion bile acids, increases bile acid faecal excretion, and reduces total cholesterol and LDL cholesterol levels. Sevelamer carbonate can be used for the research of hyperphosphataemia, hyperparathyroidism, chronic renal failure, kidney disease, and type 2 diabetes .
loading...
    loading...
Cat. No.: HY-106288
CAS No.: 172867-62-8
Purity:  99.05%
Target:  

PTHR

Research Areas:  

Cancer

Human PTHrP-(1-36) is a secretory form of PTHrP with anticalciuric effects. Human PTHrP-(1-36) enhances beta cell function and proliferation. Human PTHrP-(1-36) can be used in the research of humoral hypercalcemia of malignancy (HHM) and hyperparathyroidism .
loading...
    loading...
Cat. No.: HY-148350
CAS No.: 3032750-17-4
Purity:  99.47%
Target:  

PTHR

Research Areas:  

Cancer

DS69910557 is a potent, selective and orally activehuman parathyroid hormone receptor 1 (hPTHR1) antagonist. DS69910557 has antagonistic activity for PTHR1 with an IC50 value of 0.08 μM. DS69910557 can be used for the research of hyperparathyroidism, hypercalcemia of malignancy and osteoporosis .
loading...
    loading...
Cat. No.: HY-109106A
CAS No.: 2052969-18-1
Purity:  99.91%
Synonyms: SK-1403; AJT240; PLS240
Target:  

CaSR

Research Areas:  

Endocrinology

Upacicalcet sodium is a non-peptide calcimimetic that acts as a CaSR agonist (EC50 = 10.8 nM). Upacicalcet sodium reduces serum intact parathyroid hormone (iPTH) and serum Ca 2+ levels, reducing hypocalcemia and gastrointestinal complications. Upacicalcet sodium sodium improves vascular calcification and bone disorders in the Adenine (HY-B0152)-induced secondary hyperparathyroidism (SHPT) rat model. Upacicalcet sodium sodium inhibits cortical pore formation and reduces bone fibrosis in rats with chronic kidney disease (CKD). Upacicalcet sodium is useful for studying SHPT .
loading...
    loading...
Cat. No.: HY-P1189
CAS No.: 154303-05-6
Echistatin is a naturally derived RGD-containing snake venom peptide. Echistatin exhibits an IC50 of 0.6 nM against mouse αvβ3 integrin, and acts as an antagonist against αvβ3, αII3, α5β1 integrins, pp125 FAK and paxillin. Echistatin reduces the phosphorylation of pp125 FAK and paxillin, inhibits the autophosphorylation and kinase activity of pp125 FAK, and weakens its binding to pp60src and paxillin. Echistatin disrupts the actin cytoskeleton and focal adhesions, induces melanoma cell detachment from fibronectin, and regulates cell adhesion and motility. Echistatin inhibits osteoclast maturation and migration, bone resorption, platelet aggregation, bone loss, as well as adhesion and metastasis of Lewis lung cancer cells; it also increases the number of osteoclasts and bone coverage area in mice with secondary hyperparathyroidism. Echistatin can be used in research related to melanoma, lung cancer and secondary hyperparathyroidism .
loading...
    loading...
Cat. No.: HY-P1189A
Echistatin TFA is a naturally derived RGD-containing snake venom peptide. Echistatin TFA exhibits an IC50 of 0.6 nM against mouse αvβ3 integrin, and acts as an antagonist against αvβ3, αII3, α5β1 integrins, pp125 FAK and paxillin. Echistatin TFA reduces the phosphorylation of pp125 FAK and paxillin, inhibits the autophosphorylation and kinase activity of pp125 FAK, and weakens its binding to pp60src and paxillin. Echistatin TFA disrupts the actin cytoskeleton and focal adhesions, induces melanoma cell detachment from fibronectin, and regulates cell adhesion and motility. Echistatin TFA inhibits osteoclast maturation and migration, bone resorption, platelet aggregation, bone loss, as well as adhesion and metastasis of Lewis lung cancer cells; it also increases the number of osteoclasts and bone coverage area in mice with secondary hyperparathyroidism. Echistatin TFA can be used in research related to melanoma, lung cancer and secondary hyperparathyroidism .
loading...
    loading...
Cat. No.: HY-76585
CAS No.: 2070009-67-3
Paricalcitol-d6 is the deuterium labeled Paricalcitol. Paricalcitol is a agent used for the prevention and treatment of secondary hyperparathyroidism (excessive secretion of parathyroid hormone) associated with chronic renal failure .
loading...
    loading...
Cat. No.: HY-75992
CAS No.: 74007-20-8
trans-Doxercalciferol is an isomer of Doxercalciferol (HY-32348). Doxercalciferol is a vitamin D receptor agonist. Doxercalciferol reduces proteinuria, podocyte injury, mesangial expansion, extracellular matrix accumulation, macrophage infiltration, oxidative stress, proinflammatory cytokines, profibrotic growth factors, renal neutral lipid accumulation, albuminuria and glomerulosclerosis. Doxercalciferol alleviates high-salt diet-induced myocardial hypertrophy. trans-Doxercalciferol is used for the research of diet-induced obesity-related nephropathy, diabetic nephropathy, myocardial hypertrophy, cardiac dysfunction and secondary hyperparathyroidism .
loading...
    loading...
Cat. No.: HY-17613R
CAS No.: 870964-67-3
Synonyms: KHK7580 (Standard)
Research Areas:  

Metabolic Disease

Evocalcet (Standard) is the analytical standard of Evocalcet. This product is intended for research and analytical applications. Evocalcet (KHK7580) is an orally active calcium sensing receptor (CaSR) agonist. Evocalcet inhibits the secretion of parathyroid hormone (PTH) from parathyroid gland cells. Evocalcet can be used for the research of hyperparathyroidism .
loading...
    loading...
Cat. No.: HY-P1955
CAS No.: 1262780-97-1
Synonyms: Velcalcetide; AMG 416; KAI-4169
Target:  

CaSR

Research Areas:  

Metabolic Disease

Etelcalcetide (AMG 416; KAI-4169) is a synthetic calcimimetic as an activator of the calcium sensing receptor (CaSR). Etelcalcetide is effective in lowering parathyroid hormone (PTH) concentrations in patients receiving dialysis with secondary hyperparathyroidism receiving hemodialysis, which is promising for research in the field of secondary hyperparathyroidism and chronic kidney disease .
loading...
    loading...
Cat. No.: HY-131206
CAS No.: 2460353-87-9
Target:  

PTHR

Research Areas:  

Metabolic Disease Endocrinology

DS37571084 is an orally active and potent antagonist of the parathyroid hormone type 1 receptor (PTHR1), with an IC50 value of 0.17 μM. DS37571084 can be used for the study of hyperparathyroidism .
loading...
    loading...
Cat. No.: HY-117851
CAS No.: 1253901-26-6
Purity:  99.97%
Target:  

CaSR

Research Areas:  

Metabolic Disease Endocrinology

AC-265347 is a calcium-sensing receptor (CaSR) agonist and positive allosteric modulator (ago-PAM) with the functional affinity (pKB) of 5.1. AC-265347 can be used for the research of hyperparathyroidism and related diseases .
loading...
    loading...
Cat. No.: HY-13995
CAS No.: 52757-95-6
Target:  

FXR

Research Areas:  

Metabolic Disease Endocrinology

Sevelamer is an orally active polymeric phosphate binder and bile acid sequestrant. Sevelamer binds dietary phosphate in the gastrointestinal tract, reducing phosphate absorption and serum phosphorus levels, and reduces urinary phosphate excretion. Sevelamer binds polyanion bile acids, increases bile acid faecal excretion, and reduces total cholesterol and LDL cholesterol levels. Sevelamer can be used for the research of hyperphosphataemia, hyperparathyroidism, chronic renal failure, kidney disease, and type 2 diabetes .
loading...
    loading...
Cat. No.: HY-109106
CAS No.: 1333218-50-0
Synonyms: SK-1403 free acid; AJT240 free acid; PLS240 free acid
Target:  

CaSR

Research Areas:  

Endocrinology

Upacicalcet is a non-peptide calcimimetic that acts as a CaSR agonist (EC50 = 10.8 nM). Upacicalcet reduces serum intact parathyroid hormone (iPTH) and serum Ca2+ levels, reducing hypocalcemia and gastrointestinal complications. Upacicalcet improves vascular calcification and bone disorders in the Adenine (HY-B0152)-induced secondary hyperparathyroidism (SHPT) rat model. Upacicalcet inhibits cortical pore formation and reduces bone fibrosis in rats with chronic kidney disease (CKD). Upacicalcet is useful for studying SHPT .
loading...
    loading...
Cat. No.: HY-161113
CAS No.: 3079395-76-6
Target:  

CaSR

Research Areas:  

Metabolic Disease

Z8554052021 (compound 2021) is a potent CaSR and indeed GPCR positive allosteric modulator (PAM) with an EC50 of 3.3 nM. Z8554052021 has the potential for hyperparathyroidism research .
loading...
    loading...